Auxano Advisors’s Boston Scientific BSX Stock Holding History

Auxano Advisors’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,504	Closed	-$239K	–	200
2025 Q4	$239K	Sell	2,504 -9	-0.4%	-$882	0.05%	173
2025 Q3	$245K	Buy	2,513 +63	+3%	+$6.52K	0.05%	154
2025 Q2	$263K	Buy	2,450 +72	+3%	+$7.29K	0.06%	139
2025 Q1	$240K	Hold	2,378	–	–	0.06%	143
2024 Q4	$212K	Buy	+2,378	New	+$209K	0.05%	158

Other funds holding BSX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Auxano Advisors's BSX Position: Q1 2026 in Review

Auxano Advisors sold out of Boston Scientific (BSX) in Q1 2026, closing a stake of 2,504 shares — an estimated $239K sold.

Auxano Advisors first reported a position in BSX in Q4 2024 and held it in 5 quarters. The position peaked at $263K in Q2 2025. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.

Auxano Advisors reported no remaining Boston Scientific position as of Q1 2026 after selling out during the quarter.
Auxano Advisors sold 2,504 Boston Scientific shares in Q1 2026, an estimated $239K.
Auxano Advisors first reported a position in Boston Scientific in Q4 2024 and held it in 5 quarters.
Auxano Advisors's Boston Scientific position peaked at $263K in Q2 2025.
1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.

Based on Auxano Advisors's 13F filing for Q1 2026, filed 4 May 2026.